Flurbiprofen Sodium (flurbiprofen sodium)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Flurbiprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA).
USES: This medication is used before certain types of eye surgery (such as cataract removal). It prevents the pupil of the eye from narrowing. This effect makes it easier for the doctor to examine the inside of the eye, to remove the cataract, and to replace it with a new lens.
Flurbiprofen belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs).
Generic name: flurbiprofen sodium
Pronunciation: (flewr-BIH-pro-fen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Flurbiprofen Sodium
Indications
The following indications are listed for Flurbiprofen Sodium:
- Prevention Of Ocular Surgery-Induced Miosis
Dosing
No dosing information is available for this tab.
Flurbiprofen sodium is applied topically to the eye as an ophthalmic solution. Care should be taken to avoid contamination of the solution container.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
The interactions between flurbiprofen sodium ophthalmic solution and other ophthalmic drugs have not been fully evaluated.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats, mice, and rabbits using oral flurbiprofen have not revealed evidence of teratogenicity. Reproduction studies in rats using oral flurbiprofen dosages of 0.4 mg/kg daily (approximately 300 times the human topical daily dose) and higher have shown that the drug is embryocidal and can delay parturition; prolong gestation; produce uterine hemorrhage, gastric damage, death of dams and offspring during labor, and an increased incidence of stillbirths; reduce fetal weight; and/or slightly retard fetal growth. There are no adequate and controlled studies to date using ophthalmic flurbiprofen in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
It is not known whether flurbiprofen is distributed into milk after topical administration to the eye; however, the drug is distributed into milk after systemic administration. Because of the potential for serious adverse reactions from flurbiprofen sodium in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.